In Reply We thank Ertz-Archambault and colleagues for their interest in our recent article on long-term outcomes after high-dose chemotherapy (HDCT) with hematopoietic stem cell transplant in patients with high-risk breast cancer and 4 or more involved axillary lymph nodes.1 While the overall result of the trial does not support HDCT in patients with early breast cancer, a preplanned subgroup analysis in patients with 10 or more involved axillary lymph nodes showed a 14.6% absolute difference in 20-year overall survival. We agree that this subgroup result needs validation in a prospective trial using contemporary chemotherapy regimens in the control arm. The SUBITO trial (NCT02810743) has been designed with this aim and is currently open for enrollment. Based on our improved understanding of disease biology, the SUBITO trial includes patients with stage III, ERBB2-negative breast cancer with a BRCA1-like phenotype.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Steenbruggen TG, Steggink LC, Sonke GS. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer—Reply. JAMA Oncol. 2020;6(8):1300. doi:10.1001/jamaoncol.2020.1649
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.